Stockscreener 앱 받기
10.44
0.75%
-0.010
전일 마감가:
$10.45
열려 있는:
$10.59
하루 거래량:
538.98K
Relative Volume:
0.40
시가총액:
$741.80M
수익:
-
순이익/손실:
$-34.98M
주가수익비율:
-11.35
EPS:
-0.9199
순현금흐름:
$-32.77M
1주 성능:
+0.60%
1개월 성능:
+30.79%
6개월 성능:
+105.38%
1년 성능:
+295.86%
1일 변동 폭
$10.04
$10.63
1주일 범위
$9.60
$11.12
52주 변동 폭
$1.94
$11.61
Immix Biopharma Inc Stock (IMMX) Company Profile
명칭
Immix Biopharma Inc
전화
(888) 958-1084
주소
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
10.42 | 736.10M | 0 | -34.98M | -32.77M | -0.9199 |
VRTX
Vertex Pharmaceuticals Inc
|
520.41 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
670.00 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
925.27 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.90 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-25 | 개시 | Morgan Stanley | Overweight |
| 2026-03-09 | 개시 | Citizens | Mkt Outperform |
| 2026-02-09 | 개시 | Mizuho | Outperform |
Immix Biopharma Inc 주식(IMMX)의 최신 뉴스
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to Russell 2000 Index - marketscreener.com
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to Russell 2500 Growth Benchmark - marketscreener.com
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to Russell 2000 Growth Benchmark - marketscreener.com
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to Russell 3000E Growth Benchmark - marketscreener.com
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to Russell 3000 Growth Benchmark - marketscreener.com
Immix Biopharma, Inc. Actuals & Estimates (NASDAQ:IMMX) - TradingView
IMMX Forecast — Price Target — Prediction for 2027 - TradingView
Immix Biopharma Inc (IMMX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immix Biopharma analyst bullish but flags safety, adoption questions - MSN
All you need to know about Immix Biopharma (IMMX) rating upgrade to buy - MSN
All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy - Yahoo Finance
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Wall Street analysts think Immix Biopharma (IMMX) could surge 113.58%: Read this before placing a bet - MSN
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions - Benzinga
BofA initiates Immix Biopharma stock with buy rating on AL amyloidosis drug - Investing.com UK
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet - Yahoo Finance
Immix Biopharma, Inc. Stock 12‑Month Price Target Raised to $19.79, Implies 117% Upside - TradingView
IMMX Initiates Coverage by B of A Securities -- Rating Set to Bu - GuruFocus
This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
BofA Securities Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $27 - Moomoo
Immix Biopharma Inc (IMMX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immix Biopharma Inc (IMMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immix Biopharma Inc (IMMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IMMX Initiates Coverage On LifeSci Capital -- Rating at Outperfo - GuruFocus
Immix Biopharma Inc (IMMX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immix Biopharma Inc (IMMX) Institutional Confidence - TradingKey
Immix Biopharma Inc (IMMX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immix Biopharma Inc (IMMX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immix Biopharma Inc (IMMX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immix Biopharma Initiated at Outperform by LifeSci Capital - Moomoo
IMMX Q1 2026 Earnings: EPS Beat Reflects Cost Discipline Amid Pre-Revenue Biotech Pipeline ProgressProfit Guidance Range - newsline.com
IMMX Q1 2026 Earnings: Biotech Reports Narrower-than-Expected Loss, Shares GainEPS Estimate Trend - newsline.com
Immix Biopharma Surges 5.3% as Biotech Sentiment Lifts IMMXProfit Surge Picks - newsline.com
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Wall Street analysts see a 120.59% upside in Immix Biopharma (IMMX): Can the stock really move this high? - MSN
What's going on with Immix Biopharma stock Thursday? - MSN
Janus Henderson files 13G/A: 9.09M shares of Immix Biopharma (IMMX) - Stock Titan
IMMX News | IMMIX BIOPHARMA INC (NASDAQ:IMMX) - ChartMill
These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations - Seeking Alpha
IMMX Technical Analysis | Trend, Signals & Chart Patterns | IMMIX BIOPHARMA INC (NASDAQ:IMMX) - ChartMill
Immix Biopharma, Inc. Files Form 8-K Announcing Election of Directors and Corporate Details (May 2026) - Minichart
Immix Biopharma Shareholders Back Board and Auditor at AGM - TipRanks
Immix Biopharma (NASDAQ: IMMX) posts 2026 annual shareholder voting outcomes - Stock Titan
Immix Biopharma (IMMX) awards RSUs and stock options to director Helen Adams - Stock Titan
Immix Biopharma (IMMX) director Carey Ng awarded RSUs, 12,500-share option - Stock Titan
Immix Biopharma (NASDAQ: IMMX) grants RSUs and stock options to director - Stock Titan
Immix Biopharma (IMMX) CFO, President awarded 500,000 stock options at $8.78 - Stock Titan
Immix Biopharma (IMMX) director receives 6,250 RSUs and 12,500 options - Stock Titan
Immix Biopharma (IMMX) awards CEO 500,000 stock options at $8.78 strike - Stock Titan
Immix Biopharma (IMMX) director awarded RSUs and stock options in new grants - Stock Titan
Immix Biopharma (IMMX) board member receives new RSU and stock option awards - Stock Titan
Immix Biopharma Inc (IMMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immix Biopharma Inc 주식 (IMMX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Dec 10 '25 |
Buy |
6.58 |
770 |
5,067 |
291,429 |
| Rachman Ilya M | CEO and Chairman |
Sep 17 '25 |
Buy |
2.02 |
2,500 |
5,050 |
1,140,937 |
| Morris Gabriel S | CFO |
Sep 16 '25 |
Buy |
1.97 |
2,600 |
5,122 |
290,659 |
0.82%
0.85%
자본화:
|
볼륨(24시간):